OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

OKYO Pharma filed its annual report for fiscal year ended March 31, 2026, announcing a strengthened cash position of $20.6 million following a $22 million capital raise in February 2026. The company is fully funded to complete its NEPTUNE Phase 3 pivotal trial for urcosimod in neuropathic corneal pain, with trial initiation planned for the second half of 2026. The trial will enroll approximately 111 patients and is designed as a potential single-trial registration pathway supported by positive FDA feedback.